PMFPost-PV-MFPost-ET-MF
Conditions
Interventions
Gecacitinib:NA
Control:NA
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Aged 18 years or older,male or female; 2.Patients diagnosed with PMF according to WHO(2016 edition),or patients diagnpsed with post-pv-mf or post-et-mf according to iwg-mrt standard; 3.Patients with medium-risk -1or medium-risk-2 or high-risk myelofibrosis were evaluated according to dipss grouping criteria; 4.The expected survival time is more than 24 weeks; 5.ECOG score 0-2; 6.Peripheral blood protocells 10%; 7.Patients who have received JAK inhibitor treatment before; 8.Patients who uses Gecacitinib to treat MF; 9.Voluntarily sign the informed consent in accordance with the requirements of the ethics committee; 10.In addition, 10 healthy people were used as controls.
Exclusion criteria
Exclusion criteria: 1.Patients with autoimmune disease at the time of screening or in a prior medical history; 2.Screening for bacterial, viral, parasitic or fungal infections requiring treatment with any clinical symptoms; 3. HIV positive; 4.Women who are planning to become pregnant or who are pregnant or lactating, and those who were unable to use effective contraceptives throughout the trial; 5. Patients with other serious diseases that the researchers believe may affect patient safety or compliance; 6. Suspected allergic to Gecacitinib hydrochloride or similar drugs; 7.Select those who have participated in the clinical trials of other new drugs or medical devices within the first 12 weeks; 8.Use of any immunosuppressant other than glucocortex within 2 weeks prior to enrollment;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cellular immune related indicators; | — |
Secondary
| Measure | Time frame |
|---|---|
| Effectiveness;Safety; | — |
Countries
China
Contacts
Public ContactYang Yunfan
West China Hospital of Sichuan University
Outcome results
None listed